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a b s t r a c t
Introduction and objectives: Universal vaccination at birth and in infancy is key to the elimination of chronic
hepatitis B infection. We aimed to assess hepatitis B immune-prophylaxis and perinatal transmission
knowledge, in a large and ethnically diverse cohort of previously pregnant North American women,
chronically infected with hepatitis B.
Materials and methods: The Hepatitis B Research Network (HBRN) is comprised of 28 Clinical Centers in
the United States and Canada. Female cohort participants were administered a questionnaire to assess:
(1) their assertion of knowledge regarding HBV prophylaxis at birth, testing, and diagnosis of hepatitis B
in their children, and (2) the percentage of afﬁrmative to negative responses for each of the HBV-related
interventions her child may have received. The relationship between asserted knowledge, actions taken
and maternal demographics were assessed.
Results: A total of 351 mothers with 627 children born in or after 1992 were included. Median age at
enrollment was 39.8 years. Mothers were mostly foreign-born with the largest percentage from Asia
(73.4%) and Africa (11.7%). Of the 627 children, 94.5% had mothers who asserted that they knew whether
their child had received HBIG or HBV vaccine at birth, for 88.8% of the children, their mothers indicated
that they knew if their child was tested for HBV and for 84.5% of children, their mothers knew if the child
was diagnosed with HBV infection. Among children whose mothers asserted knowledge of their HBV
management, 95.3% were reported to have received HBIG or HBV vaccine, 83.4% of children were said
to have been tested for HBV, and 4.8% of children were said to have been diagnosed with HBV. Younger
maternal age was the only factor signiﬁcantly associated with higher percentage of children for whom
mothers reported knowledge of testing (p = 0.02) or diagnosis of HBV (p = 0.02).
Conclusions: While high percentages of North American children had mothers asserting knowledge of
HBV prophylaxis and testing, knowledge gaps remain, with mothers of 5.5–15.5% of children lacking
knowledge of key components of the HBV prevention and diagnosis in the perinatal setting. Targeted
education of HBsAg-positive mothers may aid in closing this gap and reducing vertical transmission.
© 2020 Fundación Clı́nica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Hepatitis B virus (HBV) infects over 240 million individuals
worldwide [1] and chronic hepatitis B (CHB) is a signiﬁcant cause
of end stage liver disease and liver cancer. Prevention of vertical
transmission of HBV is crucial for the elimination of chronic hepatitis B and its associated morbidity and mortality [2]. In 2014, the
global coverage of HBV vaccination at birth was estimated at 38%,
and up to 30 million newborns were still unvaccinated in countries
that provided universal birth dose vaccine as part of their national
immunization programs [3].
In the U.S. [4] and Canada [5], universal childhood HBV vaccination has been recommended since 1991. However, the current
estimated universal birth dose coverage in the U.S. remains suboptimal at about 71% [6,7].
Speciﬁc recommendations and implementation strategies vary
by country. Some countries recommend that the combination of
hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) be
administered to the infants of mothers positive for HBsAg (65):
the Advisory Committee on Immunization Practices (ACIP) recommends both within 12 h of delivery [8]. The American Association
for the Study of Liver Disease and the ACIP recommend HBsAg and
anti-HBs testing for children born to HBsAg-positive women when
they are at 9–12 months of age [9,10], and the ACIP also recommends counseling HBsAg positive mothers regarding the need for
postnatal vaccination and HBIG, completing vaccination series, and
post-vaccination serologic testing [7].
Limited studies have shown that a proportion of expectant
mothers from mostly endemic countries have suboptimal knowledge related to HBV infection and its transmission [9–11]. For
example, 76% of pregnant women in Nigeria had inadequate
HBV knowledge [8] and in a recent study from China, 20% of
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pregnant women were not aware that HBV can be transmitted from mother to infant; however, over 80% were willing to
be screened for HBV and have their babies receive HBV vaccine and HBIG [11]. Moreover, certain factors such as maternal
age, education, occupation and family set-up may be associated
with knowledge and understanding of HBV and the maternalto-child transmission risk [10]. There is a scarcity of data on
HBV-infected mothers’ knowledge of the use of immune prophylaxis and perinatal transmission in a low endemic area like North
America.
We aimed to assess the overall knowledge and factors associated
with knowledge of hepatitis B immune prophylaxis and perinatal transmission in a large and ethnically diverse North American
cohort of previously pregnant women with CHB who were enrolled
in the Hepatitis B Research Network (HBRN) Cohort Study. Evaluating gaps in maternal knowledge is critical to implement effective
prevention strategies and to enhance the recommended immune
prophylaxis programs and limit maternal transmission of HBV in
high-risk populations.
2. Material and methods
The Hepatitis B Research Network (HBRN) is comprised of 28
clinical centers (21 adult and 7 pediatric centers) in the United
States and Canada and a Data Coordinating Center (DCC). The HBRN
includes a cohort of adults and children who were HBsAg positive at enrollment [12]. Women included in this analysis were
enrolled between January 19, 2011 and April 11, 2016. The institutional review board (IRB) of each participating institution approved
the protocol of this research study, and each subject gave written
informed consent for their participation.

HBRN Adult Cohort
HBsAg+ at baseline
967 females
Excluded 372 females
• Acute HBV (n = 16)
• No or unknown pregnancy history (n = 245)
• Currently pregnant (n = 53)
• No live birth (n = 35)
• No pregnancy questionnaire (n = 23)

At least 1 live birth
595 mothers
(1330 children)
Excluded 244 mothers (620 children)
• 102 mothers with no birth years for any of their
children (287 children)
• 142 mothers with all children born before 1992
(333 children)

Excluded 83 children born before 1992

Analytic sample
At least 1 live birth in 1992 or after
351 mothers
(627 children)
Fig. 1. Study ﬂowchart for maternal pregnancy knowledge in the HBRN.
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Only women with a completed pregnancy in or after 1992 (the
year after the ACIP recommendation for HBV vaccination in the
perinatal period was initiated [4] and who completed the 3 item
questionnaire as part of an extensive data collection regarding the
natural history of HBV infection in pregnancy (see Appendix for the
questionnaire) were included (see Fig. 1). The questionnaire, which
was administered by a study coordinator with help from an interpreter if needed, inquired about mothers’ knowledge regarding her
children.
Speciﬁcally, for each of their children, mothers were asked 3
questions: whether the child: 1. received HBIG or HBV vaccine at
birth, 2. was tested for hepatitis B, and 3. was diagnosed with hepatitis B. For each question, mothers could respond “Yes,” “No,” or
“Do not know.” Thus, the questionnaire measured, two points: A)
Assertion of knowledge (“Yes” or “No” response) versus lack of
knowledge (“Do not know”) by the mother for each child born
in 1992 or after, and B) For mothers that asserted knowledge
(“Yes” or “No” response), the percentage of afﬁrmative to negative
responses for each of the HBV-related interventions her child may
have received (Fig. 2).
As the children of these mothers were not included in the HBRN
cohort, the accuracy of the mother’s information was not assessed.
Our questionnaire focused on the mother’s knowledge of her child’s
treatment as the source of truth for future health care providers
seeing the child. So, for example, the questionnaire inquires of the
mother whether each child received immunoprophylaxis, but it is
not known whether or not each child actually did since the children
are not included in the HBRN cohort.
The mother’s demographics were examined to gain insight into
potential factors associated with the survey responses. The factors
assessed were age of the mother at survey completion, race, income
level, education level, birth continent, child’s birthplace, mother’s
HBV status the year of the child’s birth, and the knowledge of the
source of the mother’s HBV infection.
2.1. Statistical analysis
Distributions of maternal characteristics are reported as frequencies and percentages for categorical data or as minimum,
maximum, and quartiles (25th, median, 75th) for continuous data.
Results of knowledge and action are presented as predicted percentages of children with 95% conﬁdence intervals obtained from
generalized estimating equations (GEE) to account for correlation
of outcomes among children within mothers. p-Values are reported
from unadjusted models. A p-value less than 0.05 was considered
to be statistically signiﬁcant. All analyses were performed using
statistical analysis software (SAS).
3. Results
3.1. Study population
Between January 2011 and April 2016, 967 HBsAg-positive
women were enrolled in the HBRN adult cohort study (Fig. 1). After
excluding women with acute HBV infection and those who had

Table 1
Characteristics of the mothers (n = 351).
Maternal characteristics

n (% of mothers)

Age at visit (years)
18–40
>40

178 (50.7)
173 (49.3)

Age at visit (years)
Median
(25th, 75th percentile)
(minimum, maximum)

39.8
(34.1, 46.1)
(19.4, 67.6)

Race
White
Black/African-American
Asian
American Indian
Hawaiian
Mixed

14 (4.0)
47 (13.4)
278 (79.2)
1 (0.3)
7 (2.0)
4 (1.1)

Continent of birth
Africa
Asiaa
Europe
North America
South America
Australia

n = 350
41 (11.7)
257 (73.4)
2 (0.6)
43 (12.3)
1 (0.3)
6 (1.7)

Mode of HBV transmission
Vertical transmission
Horizontal transmission
Adult household contact
Sexually transmitted
Occupational
Medical/surgical
Transfusion
Injection drug use
Cosmetic Procedure

n = 261
170 (65.1)
69 (26.4)
5 (1.9)
5 (1.9)
1 (0.4)
5 (1.9)
4 (1.5)
0 (0.0)
2 (0.8)

Education level
Less than high school
High school or equivalent (GED)
Some college or equivalent
Bachelor’s degree or higher

n = 343
62 (18.1)
58 (16.9)
53 (15.5)
170 (49.6)

a
Asian Countries – number of mothers: China: 98, Vietnam: 78, Philippines: 17,
South Korea: 14, Taiwan: 16, Hong Kong: 9, Thailand: 4, Mongolia: 4, Cambodia: 3,
Other: 14.

no live births in 1992 or later, the ﬁnal study group consisted of
351 mothers who completed the pregnancy questionnaire with 627
children born in 1992 or later. Among the 351 mothers were 124
who had only one live birth in or after 1992 and 227 women with
multiple live births, at least one of which was in or after 1992.
The median age of mothers when they completed the pregnancy questionnaire was 39.8 years (51% between 18 and 40 years,
49% older than 40 years). Mothers were mostly Asian (79.2%) or
Black/African American (13.4%). The majority were foreign-born
with the mother’s country of birth Asia in 73.4% and Africa in
11.7%. The presumed route of maternal HBV infection was vertical
transmission for 65.1% of the 261 mothers for whom a mode was
recorded. The education level was reported in 343 mothers with
49.6% having a bachelor’s degree education or higher (Table 1).

Assertion of Knowledge (%) = η of mothers who Asserted Knowledge (“Yes” or “No” response)
η of total mothers surveyed

Reported Affirmative (%) = η of Affirmative Response (“Yes”

η of mothers who Asserted Knowledge

Fig. 2. Equations utilized for “Assertion of Knowledge” and “Reported Afﬁrmative”, as seen in Tables 2A, 2B, 2C.
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Table 2A
Associations of maternal characteristics and pregnancy knowledgea and reported afﬁrmative.b
Pregnancy knowledge outcomes

Was child tested for hepatitis B?

Responses used for analysis

Knowledge
(n = 627)

Reported afﬁrmative
(n = 557)

%c of children (95% conﬁdence
intervals)

88.8 (85.1–91.6)
% of children

83.4 (79.0–87.0)
% of children

Mother’s age at visit (years)
18–40
>40

p = 0.02
92.7
84.7

p = 0.04
87.3
79.0

Race
Asian
Other
Black/African-American
White
American Indian/Hawaiian/Mixed

p = 0.35
90.0

p = 0.53
84.0

83.2
92.7
78.9

80.0
92.0
70.7

Income (thousand dollars)
<50
50 to <100
≥100

n = 486, p = 0.81
89.1
92.3
89.3

n = 439, p = 0.91
84.3
81.9
84.7

Education level
Less than high school
High school or equivalent
Some college or higher

n = 616, p = 0.54
86.3
86.2
90.2

n = 549, p = 0.41
87.9
78.4
82.9

Continent of mother’s birth
Asia
Other
Africa
North America
Europe/South America/Australia

n = 626, p = 0.22
89.1

n = 556, p = 0.29
84.1

80.8
95.3
83.0

89.1
78.4
63.3

Infant’s birthplace
US/Canada OR same year as mother immigration to US/Canada
Elsewhere

n = 564, p = 0.19
89.6
87.8

n = 505, p = 0.17
84.1
76.7

Mothers’ HBV status in the year of child’s birth
Diagnosed with HBV
Not yet diagnosed

n = 571, p = 0.74
89.4
90.5

n = 513, p = 0.14
85.1
76.1

Mothers’ mode of transmission
Known
Unknown

p = 0.99
88.8
88.8

p = 0.90
83.6
83.0

a

Knowledge: Estimated percentages of children whose mothers asserted that they knew whether or not child was tested, diagnosed, or received vaccine, respectively.
Reported Afﬁrmative: Of children whose mother asserted knowledge, the estimated percentages of children whose mothers asserted were actually tested, diagnosed or
received vaccine, respectively.
c
Estimated percentages and p-values obtained from univariable Generalized Estimating Equations to account for correlations among children of the same mother.
b

3.2. Mothers who asserted knowledge of their child’s HBV
management

3.3. Mother’s report of action regarding children’s postnatal
management of HBV

Initially (A) the questionnaire asked the mothers whether they
had knowledge (“Yes” or “No” versus “Do not know”) of their child’s
post-natal prophylaxis, HBV testing, and HBV diagnosis. Mothers of
94.5% (95% CI: 91.6–96.4%) of the 627 children stated they knew
whether or not their children received HBV vaccine or HBIG. A
somewhat lower percentage of children had mothers who knew
their child was tested for HBV: 88.8% (95% CI: 85.1–91.6%). Finally,
84.5% (95% CI: 80.5–87.9%) of children had mothers who asserted
knowledge of whether or not their child was diagnosed with HBV.
Children of mothers who were younger (18–40 years of age
vs older) when they completed the survey were more likely to
have had their mothers report knowledge of whether or not
they were tested for HBV (p = 0.02) or were diagnosed with
HBV (p = 0.02) (Table 2A). Percentages of children whose mothers
asserted knowledge related to testing, diagnosis or immunization were not signiﬁcantly different by other variables examined
(Tables 2B and 2C).

The second point (B) measured by the questionnaire used data
from mothers who asserted knowledge (only those that answered
“Yes” or “No”) to understand their children’s management. The proportions of afﬁrmative responses to each question, adjusting for
intra-mother correlations of her children, were calculated. According to their mothers, 95.3% (95% CI: 92.6–97.1%) of children received
HBV vaccine or HBIG, 83.4% (95% CI: 79.0–87.0%) of children were
tested for HBV, and 4.8% (95% CI: 3.1–7.3%) were diagnosed with
HBV.
More highly educated mothers and mothers who had been
diagnosed with HBV before or in the same year as the child was
born, were more likely to report in the afﬁrmative that their child
received HBIG or HBV vaccine (p = 0.0001 and p = 0.04, respectively;
Table 2). Children of mothers ≤ 40 years old at study visit were more
likely to have been reported by their mothers that they underwent
HBV testing (p = 0.04). A larger percentage of children born outside the United States or Canada were reported to be diagnosed
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Table 2B
Associations of maternal characteristics and pregnancy knowledgea and reported afﬁrmativeb
Pregnancy knowledge outcomes

Was child diagnosed with hepatitis B?

Responses used for analysis

Knowledge
(n = 627)

Reported afﬁrmative
(n = 533)

%c of children (95% conﬁdence
intervals)

84.5 (80.5–87.9)
% of children

4.8 (3.1–7.3)
% of children

Mother’s age at visit (years)
18–40
>40

p = 0.02
88.9
80.1

p = 0.7577
4.5
5.1

Race
Asian
Other
Black/African-American
White
American Indian/Hawaiian/Mixed

p = 0.45
85.0

p = 0.40
5.4
2.9

Income (thousand dollars)
<50
50 to <100
≥100

n = 486, p = 0.41
82.9
90.7
83.6

n = 416, p = 0.70
6.4
5.8
3.9

Education level
Less than high school
High school or equivalent
Some college or higher

n = 616, p = 0.31
79.5
81.9
86.6

n = 525, p = 0.46
5.7
7.0
3.7

Continent of mother’s birth
Asia
Other
Africa
North America
Europe/South America/Australia

n = 626, p = 0.29
84.1

n = 532, p = 0.39
5.5
3.2

Infant’s birthplace
US/Canada OR same year as mother immigration to US/Canada
Elsewhere

n = 564, p = 0.06
85.8
77.2

n = 481, p = 0.01
3.6
14.9

Mothers’ HBV status in the year of child’s birth
Diagnosed with HBV
Not yet diagnosed

n = 571, p = 0.14
86.4
80.8

n = 492, p = 0.001
2.8
16.7

Mothers’ mode of transmission
Known
Unknown

p = 0.67
84.1
85.9

p = 0.51
4.3
6.0

83.3
92.6
70.3

81.1
93.0
71.5

a

Knowledge: Estimated percentages of children whose mothers asserted that they knew whether or not child was tested, diagnosed, or received vaccine, respectively
Reported Afﬁrmative: Of children whose mother asserted knowledge, the estimated percentages of children whose mothers asserted were actually tested, diagnosed or
received vaccine, respectively.
c
Estimated percentages and p-values obtained from univariable Generalized Estimating Equations to account for correlations among children of the same mother.
b

with HBV (14.9% vs 3.6%, p = 0.01). Children were more likely to be
reported to have been diagnosed with HBV if the mothers had not
been diagnosed with HBV by the year of the child’s birth (16.7% vs
2.8%, p = 0.001).
4. Discussion
The goal of pre-and post-natal management of children born
to women infected with HBV is to prevent vertical transmission
of HBV. The current strategy is administration of both HBIG and
the ﬁrst dose of the hepatitis B vaccine within 12 h of delivery of a
child born to a woman HBsAg positive or a woman with unknown
HBV status [7]. Versions of this strategy have been in effect since
1991 [4]. Coupled with universal screening of pregnant women and
universal vaccination, this strategy has led to substantial reductions
in both chronic HBV infection in children and has lowered the rate
of hepatocellular carcinoma [13–15]. The addition of an HBV antiviral treatment after 28–32 weeks of gestation when the pregnant
woman has a high viral load (>200,000 IU/mL or >6 log10 copies/mL)
further reduces maternal-child transmission [14].
The women in HBRN who had given birth to a child in, or after,
1992, report that, in the majority of cases, medical providers follow these requirements to limit vertical transmission of hepatitis

B. However, for 5.5% of the children born in the years after the
recommendation for universal infant vaccination in the United
States, their mothers did not know if they received HBV immunization and/or HBIG in the neonatal period and for those children
whose mother did know, 4.7% of their children did not receive
prophylaxis. Other studies have demonstrated variable rates of prophylaxis implementation. Data from the United Kingdom showed
that 99.4% of infants born to HBsAg positive women received the
birth dose of the HBV vaccine [16], however a similar retrospective analysis in Denmark showed that only 93% of children born to
HBsAg positive women were vaccinated within 48 h of birth [17].
Of more concern is the percentage of children whose mothers lack knowledge of their child’s health status with respect to
HBV prevention. In primary care clinics, mothers are often the
source of information regarding their child’s past medical care. Further, providers may experience gaps in HBV knowledge [18–20]
and management and mothers’ knowledge of disease is likely to
inﬂuence provider recommendations. Providers with higher proportions of at-risk populations in practice are more likely to be
aware of HBV testing, preventative strategies and management in
their patients. For example, having a greater than 25% proportion
of Asian population in practice has been associated with more than
double the rates of HBV testing in practice by provider report [20].
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Table 2C
Associations of maternal characteristics and pregnancy knowledgea and reported afﬁrmativeb
Pregnancy knowledge outcomes

Did child receive HBIG or HBV vaccine?

Responses used for analysis

Knowledge
(n = 627)

Reported afﬁrmative
(n = 593)

%c of children (95% conﬁdence
intervals)

94.5 (91.6–96.4)
% of children

95.3 (92.6–97.1)
% of children

Mother’s age at visit (years)
18–40
>40

p = 0.27
95.8
93.1

p = 0.052
97.5
92.9

Race
Asian
Other
Black/African-American
White
American Indian/Hawaiian/Mixed

p = 1.00
94.5
94.5

p = 0.06
96.5
91.1

Income (thousand dollars)
<50
50 to <100
≥100

n = 486, p = 0.12
92.9
97.1
98.9

n = 467, p = 0.09
91.9
95.9
99.0

Education level
Less than high school
High school or equivalent
Some college or higher

n = 616, p = 0.09
89.7
96.4
96.4

n = 587, p = 0.0001
83.8
95.0
98.4

Continent of mother’s birth
Asia
Other
Africa
North America
Europe/South America/Australia

n = 626, p = 0.70
94.0

n = 592, p = 0.16
96.2

95.2
97.6
88.5

88.0
97.5
95.4

Infant’s birthplace
US/Canada OR same year as mother immigration to US/Canada
Elsewhere

n = 564, p = 0.60
95.2
96.5

n = 539, p = 0.14
97.3
88.7

Mothers’ HBV status in the year of child’s birth
Diagnosed with HBV
Not yet diagnosed

n = 571, p = 0.19
95.5
94.3

n = 545, p = 0.04
98.3
83.5

Mothers’ mode of transmission
Known
Unknown

p = 0.03
96.0
90.0

p = 0.75
95.5
94.7

a

Knowledge: Estimated percentages of children whose mothers asserted that they knew whether or not child was tested, diagnosed, or received vaccine, respectively.
Reported Afﬁrmative: Of children whose mother asserted knowledge, the estimated percentages of children whose mothers asserted were actually tested, diagnosed or
received vaccine, respectively.
c
Estimated percentages and p-values obtained from univariable Generalized Estimating Equations to account for correlations among children of the same mother.
b

Our data demonstrate that HBV positive mothers are often unaware
of their child’s HBV status and their child’s perinatal care. Furthermore, when mothers are aware, the percentage of children who
were diagnosed with HBV differed with respect to mothers’ knowledge of their own HBV status. These data show that if mothers had
been diagnosed with HBV in the year that their child was born,
their children had a lower rate of HBV infection than children of
mothers who had not yet been diagnosed with HBV. This suggests
that mothers who knew that they had chronic HBV took actions to
prevent vertical transmission.
Thus, mothers’ lack of knowledge regarding their own HBV status and that of their child, or of their child’s status regarding HBV
preventive measures, can lead to poor recognition of key medical care issues in these children. In the USA, state immunization
databases record infant immunizations and HBIG administration,
but these data are not available unless the child remains in the
state of their birth; moreover, not all providers participate in these
databases. Thus, the child’s future medical providers may not have
the information they need to appropriately manage these children.
In particular, completing the full HBV vaccine series is challenging
[16,17,21], yet crucial to prevent acquisition of HBV by the child.
According to the mothers in our study, 4.8% of children whose
mothers asserted knowledge of the diagnosis were diagnosed with

HBV. This is similar to the documented effectiveness of immune
prophylaxis in newborns of 90–95% [24], though the mothers of
some of the children who asserted they were diagnosed with HBV
did not assert that they were vaccinated. Improving this number
may require strategies beyond current preventive programs. However, for 11.2% of the children, their mothers did not know if their
child was tested for HBV and for 15.5% of children, their mothers
did not know if they were diagnosed with HBV. Diagnosis requires
testing, generally after the third dose of HBV vaccine [7]. As patient
and provider factors are known to inﬂuence HBV care and preventative services [18–20], the fact that mothers are unsure of whether
their children were tested, raises concerns about provider-parent
communication, provider knowledge of the appropriate care of a
child at HBV risk and whether the full HBV vaccination schedule
was completed.
This study has some limitations. Maternal knowledge of neonatal HBV management is by self-report since direct data on the
children’s HBV prophylaxis, HBV status, and outcomes are not part
of this study. Therefore, the accuracy of a mothers’ report cannot
be conﬁrmed and past events may not be remembered accurately.
Additionally, as immune prophylaxis includes two possible injections (vaccine and HBIG), the data reported here do not distinguish
between receipt of only vaccine, HBIG, or both. We also do not
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have data on the number of subsequent HBV vaccine doses that
were completed. Nonetheless, no prior study has attempted to
measure gaps in HBV-infected mothers’ knowledge with respect to
mother-to-child transmission of the infection in a North American
population.
The cause of any apparent missed prophylaxis in the HBRN
sample could not be determined. Newborns may fail to receive
prophylaxis because they are seriously ill in the newborn period,
because they are below the weight threshold for vaccination or
because the mother was unaware of the recommendations [21].
Another possible explanation may be that some of the children
in this cohort were born outside North America where barriers to
effective delivery of HBV prophylaxis may exist. Another possibility
is that mothers were unaware of their child’s treatment or forgot
the events that occurred peripartum. Studies have demonstrated
both false positive and false negative memories of vaccination
among parents after a decade or more [22,23].
In conclusion, among HBV-infected women living in the United
States or Canada, approximately one-in-ten lacked knowledge
regarding the HBV testing status of their children. This knowledge
gap can be improved by educating both parents and providers of
the importance of both prevention and diagnostic algorithms. It
also emphasizes the need for providers to conﬁrm the HBV status
of all family members of a person with HBV, but especially to insure
testing of children in the family. Providing this knowledge can be
expected to improve the care of children born to HBsAg positive
mothers and ultimately contribute to the global efforts to eliminate
HBV.
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